Prognostic implications of the expression of erbB2, topoisomerase IIα and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy

Jacqueline Ming Liu, Li Tzong Chen, Anna F.Y. Li, Chew Wen Wu, Chieh Lan, Tsai Rong Chung, Her Shyong Shiah, Kuan Der Lee, Tsang Wu Liu, Jacqueline Whang Peng

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: This retrospective study aimed to ascertain the expression of erbB2 in relation to topoisomerase IIα (T2α) and thymidylate synthase (TS) markers in 30 consecutive metastatic gastric cancer patients with a specimen available for study. Methods: All patients had been entered on consecutive chemotherapeutic clinical trials that were all 5-fluorouracil based. The specimens were evaluated by fluorescence in situ hybridization to ascertain erbB2 and T2α gene amplification, and by immunohistochemical staining for T2α and TS protein expression. Results: erbB2 amplification was detected in 16.7% of specimens, with co-amplification of the T2α gene in 40%, and 44% had undetectable TS protein expression. Kaplan-Meier survival curves showed significantly prolonged overall survival in patients with erbB2 and T2a gene amplification, T2α protein overexpression and absence of TS protein expression (P = 0.0011, P = 0.0048, P = 0.0061 and P = 0.0267, respectively, by log rank test). There was a positive correlation between erbB2 amplification and T2α amplification, T2α protein overexpression, and a trend towards absence of TS expression (P = 0.0001, P = 0.003 and P = 0.066 by Fisher's exact test). Conclusion: High dose fluorouracil/leucovorin-based chemotherapy may have the potential to reverse the adverse effects resulting from erbB2 gene amplification in gastric cancer.

Original languageEnglish
Pages (from-to)727-732
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume34
Issue number12
DOIs
Publication statusPublished - 2004
Externally publishedYes

Fingerprint

Thymidylate Synthase
Type II DNA Topoisomerase
Fluorouracil
Gene Amplification
Stomach Neoplasms
erbB-2 Genes
Proteins
Therapeutics
Leucovorin
Kaplan-Meier Estimate
Fluorescence In Situ Hybridization
Retrospective Studies
Clinical Trials
Staining and Labeling
Drug Therapy
Survival

Keywords

  • erbB2
  • Gastric cancer
  • Survival
  • Thymidylate synthase
  • Topoisomerase IIα

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Prognostic implications of the expression of erbB2, topoisomerase IIα and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy. / Liu, Jacqueline Ming; Chen, Li Tzong; Li, Anna F.Y.; Wu, Chew Wen; Lan, Chieh; Chung, Tsai Rong; Shiah, Her Shyong; Lee, Kuan Der; Liu, Tsang Wu; Peng, Jacqueline Whang.

In: Japanese Journal of Clinical Oncology, Vol. 34, No. 12, 2004, p. 727-732.

Research output: Contribution to journalArticle

@article{fe7b818dcf994cfa8681a66a322f6858,
title = "Prognostic implications of the expression of erbB2, topoisomerase IIα and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy",
abstract = "Objective: This retrospective study aimed to ascertain the expression of erbB2 in relation to topoisomerase IIα (T2α) and thymidylate synthase (TS) markers in 30 consecutive metastatic gastric cancer patients with a specimen available for study. Methods: All patients had been entered on consecutive chemotherapeutic clinical trials that were all 5-fluorouracil based. The specimens were evaluated by fluorescence in situ hybridization to ascertain erbB2 and T2α gene amplification, and by immunohistochemical staining for T2α and TS protein expression. Results: erbB2 amplification was detected in 16.7{\%} of specimens, with co-amplification of the T2α gene in 40{\%}, and 44{\%} had undetectable TS protein expression. Kaplan-Meier survival curves showed significantly prolonged overall survival in patients with erbB2 and T2a gene amplification, T2α protein overexpression and absence of TS protein expression (P = 0.0011, P = 0.0048, P = 0.0061 and P = 0.0267, respectively, by log rank test). There was a positive correlation between erbB2 amplification and T2α amplification, T2α protein overexpression, and a trend towards absence of TS expression (P = 0.0001, P = 0.003 and P = 0.066 by Fisher's exact test). Conclusion: High dose fluorouracil/leucovorin-based chemotherapy may have the potential to reverse the adverse effects resulting from erbB2 gene amplification in gastric cancer.",
keywords = "erbB2, Gastric cancer, Survival, Thymidylate synthase, Topoisomerase IIα",
author = "Liu, {Jacqueline Ming} and Chen, {Li Tzong} and Li, {Anna F.Y.} and Wu, {Chew Wen} and Chieh Lan and Chung, {Tsai Rong} and Shiah, {Her Shyong} and Lee, {Kuan Der} and Liu, {Tsang Wu} and Peng, {Jacqueline Whang}",
year = "2004",
doi = "10.1093/jjco/hyh137",
language = "English",
volume = "34",
pages = "727--732",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Prognostic implications of the expression of erbB2, topoisomerase IIα and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy

AU - Liu, Jacqueline Ming

AU - Chen, Li Tzong

AU - Li, Anna F.Y.

AU - Wu, Chew Wen

AU - Lan, Chieh

AU - Chung, Tsai Rong

AU - Shiah, Her Shyong

AU - Lee, Kuan Der

AU - Liu, Tsang Wu

AU - Peng, Jacqueline Whang

PY - 2004

Y1 - 2004

N2 - Objective: This retrospective study aimed to ascertain the expression of erbB2 in relation to topoisomerase IIα (T2α) and thymidylate synthase (TS) markers in 30 consecutive metastatic gastric cancer patients with a specimen available for study. Methods: All patients had been entered on consecutive chemotherapeutic clinical trials that were all 5-fluorouracil based. The specimens were evaluated by fluorescence in situ hybridization to ascertain erbB2 and T2α gene amplification, and by immunohistochemical staining for T2α and TS protein expression. Results: erbB2 amplification was detected in 16.7% of specimens, with co-amplification of the T2α gene in 40%, and 44% had undetectable TS protein expression. Kaplan-Meier survival curves showed significantly prolonged overall survival in patients with erbB2 and T2a gene amplification, T2α protein overexpression and absence of TS protein expression (P = 0.0011, P = 0.0048, P = 0.0061 and P = 0.0267, respectively, by log rank test). There was a positive correlation between erbB2 amplification and T2α amplification, T2α protein overexpression, and a trend towards absence of TS expression (P = 0.0001, P = 0.003 and P = 0.066 by Fisher's exact test). Conclusion: High dose fluorouracil/leucovorin-based chemotherapy may have the potential to reverse the adverse effects resulting from erbB2 gene amplification in gastric cancer.

AB - Objective: This retrospective study aimed to ascertain the expression of erbB2 in relation to topoisomerase IIα (T2α) and thymidylate synthase (TS) markers in 30 consecutive metastatic gastric cancer patients with a specimen available for study. Methods: All patients had been entered on consecutive chemotherapeutic clinical trials that were all 5-fluorouracil based. The specimens were evaluated by fluorescence in situ hybridization to ascertain erbB2 and T2α gene amplification, and by immunohistochemical staining for T2α and TS protein expression. Results: erbB2 amplification was detected in 16.7% of specimens, with co-amplification of the T2α gene in 40%, and 44% had undetectable TS protein expression. Kaplan-Meier survival curves showed significantly prolonged overall survival in patients with erbB2 and T2a gene amplification, T2α protein overexpression and absence of TS protein expression (P = 0.0011, P = 0.0048, P = 0.0061 and P = 0.0267, respectively, by log rank test). There was a positive correlation between erbB2 amplification and T2α amplification, T2α protein overexpression, and a trend towards absence of TS expression (P = 0.0001, P = 0.003 and P = 0.066 by Fisher's exact test). Conclusion: High dose fluorouracil/leucovorin-based chemotherapy may have the potential to reverse the adverse effects resulting from erbB2 gene amplification in gastric cancer.

KW - erbB2

KW - Gastric cancer

KW - Survival

KW - Thymidylate synthase

KW - Topoisomerase IIα

UR - http://www.scopus.com/inward/record.url?scp=14544297976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14544297976&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyh137

DO - 10.1093/jjco/hyh137

M3 - Article

C2 - 15640503

AN - SCOPUS:14544297976

VL - 34

SP - 727

EP - 732

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 12

ER -